BUZZ - Leerink says concerns over growth in the medical technology sector may overshadow third-quarter performance
路透社2026/10/09 13:06October 9 – Leerink Partners stated that, ahead of the third-quarter earnings reports, it remains cautious on the medical technology sector and pointed out that the short-term market environment is “somewhat uncertain.” The firm noted increasing competition in some markets, including the cardiac devices and diabetes care sectors; uncertainty in surgical volumes amid rising costs; weak consumer confidence; and pressure on hospital budgets due to higher interest rates. “We believe that even if third-quarter results are positive, they may be overshadowed by ongoing market concerns about profitability and growth prospects for 2027 and beyond,” the broker said. The firm believes that positive factors for specific companies could help Medtronic (MDT.N) and Tandem Diabetes Care (TNDM.O) outperform the broader industry during these sector-wide headwinds. The broker said it remains most cautious on PROCEPT BioRobotics (PRCT.O) and Insulet (PODD.O), as a slowdown in adoption and intensifying competition may lead to lowered expectations for 2027. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translation may contain errors or fail to capture the required context, Reuters does not guarantee the accuracy of automated translation texts, and they are provided merely for readers’ convenience. Reuters accepts no liability for any damage or loss resulting from the use of automated translation features.)
October 9 - ** Leerink Partners stated that they remain cautious on the medical technology sector ahead of third-quarter earnings reports, and indicated that the market environment appears “somewhat uncertain” in the short term.
** The institution pointed out that competition is intensifying in some markets (including the cardiac devices and diabetes care sectors); there is uncertainty around surgery volumes amid rising costs; consumer confidence is weak; and rising interest rates are putting pressure on hospital budgets.
** “We believe that even positive third-quarter performances could be overshadowed by ongoing concerns about profitability and growth prospects in 2027 and beyond,” the brokerage said.
** The institution believes that company-specific positive factors may help Medtronic (MDT.N) and Tandem Diabetes Care (TNDM.O) outperform the broader industry amid overall sector headwinds.
** The brokerage said it is most cautious on PROCEPT BioRobotics (PRCT.O) and Insulet (PODD.O) because slower adoption rates and increased competition could lead to downward revisions of 2027 expectations.
(To assist non-native English speakers, Reuters has automated the translation of its reports into several other languages. Because automated translation may be inaccurate or lack essential context, Reuters does not guarantee the accuracy of the automated translation and provides it for reader convenience only. Reuters assumes no responsibility for any damage or losses arising from the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
TSMC's Q3 Revenue Represents a Slightly Larger-Than-Typical Beat, Wedbush Says
10:36 AM EDT, 10/09/2026 (MT Newswires) -- Taiwan Semiconductor Manufacturing's (TSM) Q3 revenue of NT$1.494 trillion ($46.77 billion) represented a roughly 3% beat versus the brokerage's prior estimate and consensus, compared with a 1% beat in the previous quarter, Wedbush said in a Friday note. With revenue ahead of the range, Wedbush expects the quarterly gross margin to at least meet the 66% midpoint of TSMC's 65% to 67% guidance and is more likely to exceed its 66.0% estimate given better utilization rates, according to the research note. Looking ahead, Wedbush expects Q4 sales of NT$1.599 trillion and sales growth of 41% in US dollars or 43% in Taiwanese dollars. Additionally, its gross margin estimate of 65.3% sits below the consensus estimate of 66.1%, with Wedbush saying it would not be surprised if Q4 gross-margin guidance ticks modestly lower on account of headwinds the chipmaker has previously mentioned. Wedbush maintained its outperform rating with an NT$3,000 price target. Price: 453.01, Change: -4.98, Percent Change: -1.09
BUZZ-Delta Air Lines shares fall after sharply lowering full-year earnings guidance
Latest Updates October 9 – ** Delta Air Lines (DAL.N) shares fell 3% to $79.67 ** Delta Air Lines (DAL) (link) lowered its full-year adjusted profit forecast due to soaring jet fuel prices ** Peer companies United Airlines (UAL.O) and Alaska Airlines (ALK.N) shares both fell about 2.8%, while American Airlines (AAL.O) was down 2.4% ** The U.S. airline now expects 2026 adjusted earnings per share to be between $5.10-$5.60, compared to a previous expectation of $6.5-$7.5 per share ** The midpoint of the current range is $5.35 per share, below analysts’ expectation of $5.46 per share — according to data compiled by LSEG ** DAL expects its full-year fuel costs to increase by about $6 billion, up from the previous forecast of a $4 billion increase ** The company’s third-quarter adjusted earnings per share were $1.72, missing the $1.75 estimate, marking its first quarterly profit miss in two years ** Analysts tracking DAL on average give it a "Buy" rating ** As of Thursday's close, Delta Air Lines (DAL) has risen 18.4% year-to-date, the highest gain among major U.S. competitors (For the convenience of non-native English speakers, this Reuters report is automatically translated into several other languages. Due to possible errors or missing context in machine translations, Reuters makes no guarantee as to the accuracy of the translated text, which is provided for reader convenience only. Reuters is not responsible for any damage or loss caused by the use of automated translation features.)
3 Best Crypto Stocks with 120%+ Upside, According to Analysts
Crypto prices
More
